Blog Posts

Paolo Tarantino: Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer

Paolo Tarantino/X

Apr 12, 2025, 12:45

Paolo Tarantino: Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, posted on X:

“Results from OptiTROP-B01 out in Nature Medicine.

The TROP2-ADC sacituzumab tirumotecan improved PFS and OS in highly pretreated mTNBC, irrespective of Trop2 exp. Results similar to ASCENT. Approved in China, may soon also reach the west (4th topo1 ADC).”

“Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.”

Authors: Yongmei Yin, Ying Fan, Quchang Ouyang, Lihua Song, Xiaojia Wang, Wei Li, Man Li, Xi Yan, Shusen Wang, Tao Sun, Yuee Teng, Xianjun Tang, Zhongsheng Tong, Zhengkui Sun, Junyou Ge, Xiaoping Jin, Yina Diao, Gesha Liu, Binghe Xu

Paolo Tarantino: Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer

Binghe Xu cancer Gesha Liu Junyou Ge Lihua Song Man Li Nature Medicine OncoDaily Oncology Paolo Tarantino Quchang Ouyang Shusen Wang Tao Sun triple-negative breast cancer Wei Li Xi Yan Xianjun Tang Xiaojia Wang Xiaoping Jin Yina Diao Ying Fan Yongmei Yin Yuee Teng Zhengkui Sun Zhongsheng Tong

Top 10 Oncogrants of the Week: Advancing Breakthroughs in Cancer Care

Solange Peters Honored with the IASLC Paul A. Bunn, Jr. Scientific Award 2025

World Radiotherapy Awareness Day, September 7: Recognizing the Hidden Hero of Cancer Care

16 Posts Not to Miss From WCLC 2025 Part 1

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham